EGFR and non-small cell lung carcinoma: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have emerged as first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) harboring EGFR-TKI-sensitive mutations, because of their higher response rate and lower toxicity compared to conventional chemotherapy.